Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 7, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

June 30, 2025

Conditions
Substance Use DisordersOpioid Use DisorderAlcohol Use DisorderCocaine Use DisorderMethamphetamine-dependence
Interventions
COMBINATION_PRODUCT

EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance)

EDITOR includes a user-friendly cloud portal synced with the main device, providing a comprehensive training program for the orbitofrontal cortex (OFC). The main device stimulates the orbitofrontal cortex intensely, preventing habituation to smells and improving adaptability. This enhances neurobehavioral plasticity, benefiting Substance Use Disorder (SUD) outcomes. The device also features a 60% beta-caryophyllene scent for addressing issues like Alcohol Use Disorder and stimulant use disorders. With ten digital enhancements, it enables remote treatment and data collection, seamlessly transmitting information to healthcare providers through a secure, HIPAA-compliant portal.

COMBINATION_PRODUCT

CBOT with olfactory stimulants & OFC tasks

The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time combined with orbitofrontal cortex (OFC) dependent olfactory tasks.

COMBINATION_PRODUCT

CBOT Sham

CBOT Sham uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive olfactory tasks

Trial Locations (3)

20002

RECRUITING

Clinics of Dr. Edwin Chapman @ MHDG, Washington D.C.

20060

RECRUITING

Howard University, Washington D.C.

20853

ENROLLING_BY_INVITATION

Maryland Treatment Center, Rockville

All Listed Sponsors
collaborator

Howard University

OTHER

collaborator

Maryland Treatment Center

UNKNOWN

collaborator

Clinics of Dr. Edwin Chapman, MD, PC @ MHDG

UNKNOWN

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Evon Medics LLC

INDUSTRY